Traumatic brain injury biomarkers: from pipeline to diagnostic assay development - PubMed (original) (raw)
Traumatic brain injury biomarkers: from pipeline to diagnostic assay development
Monika W Oli et al. Methods Mol Biol. 2009.
Abstract
In recent years, the term proteomics is often mentioned together with biomarker discovery, as proteomic studies have the capability of identifying unique and unobvious protein biomarkers from tissues or biofluids derived from animal models or human clinical samples inflicted with various diseases. Proteomics has yielded hundreds of potential biomarker candidates. However, biomarker discovery is only the beginning of a long road for generating a validated, clinically relevant, and FDA-approved biomarker assay. Many technical, financial, legal, and regulatory hurdles have to be overcome before the components can be commercially produced (1, 2). This chapter outlines in a condensed version the steps to successfully develop clinically acceptable biomarkers, given the marker of choice withstands the rigor of developmental challenges along the road.
Similar articles
- Translation of neurological biomarkers to clinically relevant platforms.
Hayes RL, Robinson G, Muller U, Wang KK. Hayes RL, et al. Methods Mol Biol. 2009;566:303-13. doi: 10.1007/978-1-59745-562-6_20. Methods Mol Biol. 2009. PMID: 20058180 - Proteomic identification of biomarkers of traumatic brain injury.
Wang KK, Ottens AK, Liu MC, Lewis SB, Meegan C, Oli MW, Tortella FC, Hayes RL. Wang KK, et al. Expert Rev Proteomics. 2005 Aug;2(4):603-14. doi: 10.1586/14789450.2.4.603. Expert Rev Proteomics. 2005. PMID: 16097892 Review. - Proteomic analysis of traumatic brain injury: the search for biomarkers.
Prieto DA, Ye X, Veenstra TD. Prieto DA, et al. Expert Rev Proteomics. 2008 Apr;5(2):283-91. doi: 10.1586/14789450.5.2.283. Expert Rev Proteomics. 2008. PMID: 18466057 Review. - Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW, Figeys D, Vasilescu J. Lee JW, et al. Adv Cancer Res. 2007;96:269-98. doi: 10.1016/S0065-230X(06)96010-2. Adv Cancer Res. 2007. PMID: 17161683 Review. - Leveraging biomarker platforms and systems biology for rehabilomics and biologics effectiveness research.
Kobeissy FH, Guingab-Cagmat JD, Razafsha M, O'Steen L, Zhang Z, Hayes RL, Chiu WT, Wang KK. Kobeissy FH, et al. PM R. 2011 Jun;3(6 Suppl 1):S139-47. doi: 10.1016/j.pmrj.2011.02.012. PM R. 2011. PMID: 21703572 Review.
Cited by
- Toward development of clinically translatable diagnostic and prognostic metrics of traumatic brain injury using animal models: A review and a look forward.
Hajiaghamemar M, Seidi M, Oeur RA, Margulies SS. Hajiaghamemar M, et al. Exp Neurol. 2019 Aug;318:101-123. doi: 10.1016/j.expneurol.2019.04.019. Epub 2019 May 2. Exp Neurol. 2019. PMID: 31055005 Free PMC article. Review. - Application of proteomics to cerebrovascular disease.
Ning M, Lopez M, Cao J, Buonanno FS, Lo EH. Ning M, et al. Electrophoresis. 2012 Dec;33(24):3582-97. doi: 10.1002/elps.201200481. Electrophoresis. 2012. PMID: 23161401 Free PMC article. Review. - Bench-to-bedside and bedside back to the bench; coordinating clinical and experimental traumatic brain injury studies.
Agoston DV, Risling M, Bellander BM. Agoston DV, et al. Front Neurol. 2012 Feb 2;3:3. doi: 10.3389/fneur.2012.00003. eCollection 2012. Front Neurol. 2012. PMID: 22347208 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources